LIMN Liminatus Pharma, Inc.

Nasdaq liminatuspharma.com


$ 1.28 $ 0.00 (0 %)    

Tuesday, 28-Oct-2025 11:13:22 EDT
QQQ $ 630.04 $ 0.00 (0 %)
DIA $ 477.90 $ 0.00 (0 %)
SPY $ 685.78 $ 0.00 (0 %)
TLT $ 92.00 $ 0.00 (0 %)
GLD $ 364.32 $ 0.00 (0 %)
$ 1.28
$ 1.30
$ 1.27 x 775
$ 1.28 x 118
$ 1.26 - $ 1.30
$ 1.11 - $ 33.66
658,710
na
29.83M
$ -1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-04-2025 06-30-2025 10-Q
2 05-31-2025 03-31-2025 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), La Palma, CA, a clinical-stage immuno-oncology company developing next-generation CD47-bl...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. has entered into a Memorandum of Understanding (MOU) to form a research and development consortium with ...

 us-stocks-likely-to-open-higher-sp-500-sees-average-gain-of-61-in-2nd-half-expert-says

U.S. futures rose on Wednesday after a mixed close on Tuesday. Futures of major benchmark indices were trading slightly higher.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION